Artivion(AORT) - 2025 Q1 - Earnings Call Presentation

Financial Performance - Artivion reported Q1 2025 revenue of $99 million[10] - The company achieved 4% year-over-year constant currency revenue growth in Q1 2025[10] - Adjusted EBITDA for Q1 2025 was $175 million, a 1% increase year-over-year[10] - The company raised the midpoint of FY25 revenue guidance to a range of $423 million to $435 million, representing 11% to 14% year-over-year growth[13] - The company expects FY25 adjusted EBITDA to be in the range of $84 million to $91 million, growing 18% to 28% over FY24[13] Product and Geographic Growth - Stent grafts showed 19% year-over-year constant currency revenue growth[11] - On-X saw 11% year-over-year constant currency revenue growth[11] - BioGlue experienced 9% year-over-year constant currency revenue growth[11] - Latin America experienced 26% constant currency revenue growth[17] Clinical Trial and Regulatory Updates - The NEXUS TRIOMPHE trial demonstrated a 63% reduction in major adverse event rate compared to the reference performance goal[12, 18] - PMA approval for NEXUS TRIOMPHE is expected in the second half of 2026[12] - 30-day data demonstrate AMDS induced positive aortic remodeling in over 80% of patients[29]